Bio-Rad Laboratories reported third-quarter net income of $458.6 million, or $17.02 per diluted share, compared to a net loss of $(341.9) million in the prior year period. The GAAP results were significantly impacted by a non-cash gain from the change in fair market value of its investment in Sartorius AG. On a non-GAAP basis, the company reported net income of $71.5 million and diluted earnings per share of $2.65. Total net sales increased 0.5% to $656.4 million, with currency-neutral revenue growth of 0.7%. The Life Science segment saw a 2.8% decline in sales, while Clinical Diagnostics grew 2.7%. Bio-Rad operates as a global leader in life science research and clinical diagnostics products.
